Home › Funds › Assenagon Asset Management S.A. › ABT

Assenagon Asset Management S.A. position in ABT

ABBOTT LABORATORIES · Health Care

Assenagon Asset Management S.A. reported holding 5,187,488 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$512.7M, representing 0.62% of its reported portfolio and ranking #29 among its reported holdings. Assenagon Asset Management S.A. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)5.19M sh
Reported value held$512.68M
Portfolio Weight0.62%
First reportedQ3 2023
Last changeAdd
Updated2026-10-15

Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR

How Assenagon Asset Management S.A.'s ABT position evolved

Assenagon Asset Management S.A. first disclosed a stake in ABT in Q3 2023 at 535,927 shares (US$51.9M). The position peaked in Q3 2026 at 5,187,488 shares, worth US$512.7M. Across 13 filings, Assenagon Asset Management S.A. increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 5,187,488 shares valued at US$512.7M — an increase of 1,968,916 shares quarter over quarter.. Notable position changes include a 493% increase in Q2 2024 (shares rose 10% over the following quarter), a 333% increase in Q4 2025 (shares fell 18% over the following quarter), a 303% increase in Q1 2026 (shares fell 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 535.93K $51.90M New
Q4 2023 418.75K $46.09M Reduce
Q1 2024 404.87K $46.02M Reduce
Q2 2024 2.40M $249.51M Add
Q3 2024 2.28M $259.67M Reduce
Q4 2024 1.75M $197.67M Reduce
Q1 2025 1.88M $248.85M Add
Q2 2025 1.91M $259.67M Add
Q3 2025 253.59K $33.97M Reduce
Q4 2025 1.10M $137.72M Add
Q1 2026 4.43M $454.78M Add
Q2 2026 3.22M $292.05M Reduce
Q3 2026 5.19M $512.68M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Assenagon Asset Management S.A. held ABT?

Assenagon Asset Management S.A. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Assenagon Asset Management S.A.'s current position in ABT?

As of Q3 2026, Assenagon Asset Management S.A. holds 5.19M shares of ABT (ABBOTT LABORATORIES), valued at $512.68M, representing 0.62% of its reported portfolio and ranking #29.

Has Assenagon Asset Management S.A. been buying or selling ABT?

In the latest 13F filing (Q3 2026), Assenagon Asset Management S.A. increased its position in ABT. The position peaked in Q3 2026 at 5.19M shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.